Display Settings:

Format

Send to:

Choose Destination
Clin Oncol (R Coll Radiol). 2012 Oct;24(8):545-55. doi: 10.1016/j.clon.2012.05.001. Epub 2012 Jun 7.

Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer.

Author information

  • 1Institute of Cancer Research, Sutton, Surrey, UK. emma.killick@icr.ac.uk

Abstract

Prostate-specific antigen is currently commonly used as a screening biomarker for prostate cancer, but it has limitations in both sensitivity and specificity. The development of novel biomarkers for early cancer detection has the potential to improve survival, reduce unnecessary investigations and benefit the health economy. Here we review the use and limitations of prostate-specific antigen and its subtypes, urinary biomarkers including PCA3, alpha-methylacyl-CoA racemase, the TMPRSS2-ERG fusion gene and microseminoprotein-beta, and other novel markers in both serum and urine. Many of these biomarkers are at early stages of development and require evaluation in prospective trials to determine their potential usefulness in clinical practice. Genetic profiling may allow for the targeting of high-risk populations for screening and may offer the opportunity to combine biomarker results with genotype to aid risk assessment.

Copyright © 2012 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

PMID:
22682955
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk